THOUSAND OAKS, Calif., October 14, 2026
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for tabelecleucel (Tab-cel®), an investigational T-cell immunotherapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The resubmission was submitted by Atara’s partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), seeking approval of Tab-cel as a monotherapy for adult and pediatric patients aged two years and older with EBV+ PTLD who have received at least one prior therapy. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2027, under a Class 2 resubmission review. If approved, Tab-cel would be the first therapy available in the United States specifically for EBV+ PTLD, according to the company. The acceptance marks a regulatory milestone for Atara as it supports Pierre Fabre in preparing for a potential U.S. launch.
FDA Sets March 2027 Target Action Date
The FDA’s acceptance of the resubmitted BLA allows the application to proceed through regulatory review, with a target action date of March 31, 2027. The proposed indication covers adults and children aged two years and older with EBV+ PTLD who have received at least one previous therapy. Tab-cel is being developed as a single-agent treatment for this serious condition, which can occur following transplantation and is associated with Epstein-Barr virus infection. The FDA has previously granted Tab-cel Breakthrough Therapy Designation for rituximab-refractory EBV-associated lymphoproliferative disease. The therapy has also received Orphan Drug Designation for EBV-positive post-transplant lymphoproliferative disorders. These designations reflect the program’s regulatory status but do not constitute marketing approval. Atara President and Chief Executive Officer Cokey Nguyen said acceptance of the resubmission brings the company closer to potentially making the treatment available to patients in the United States. He also acknowledged the FDA’s guidance and said Atara would continue working with Pierre Fabre as the application undergoes review. The March 2027 date is the agency’s target for action on the application, not a guarantee of approval.
Tabelecleucel Targets EBV-Associated Disease
Tabelecleucel is an investigational allogeneic Epstein-Barr virus-specific T-cell immunotherapy designed to harness immune cells to address diseases associated with EBV. Atara’s platform is intended to support off-the-shelf cell therapies that can be delivered from inventory rather than requiring each treatment to be individually manufactured for a patient. The company’s approach uses T cells directed against EBV, which is implicated in certain cancers and lymphoproliferative disorders. The proposed Tab-cel indication is for patients with EBV+ PTLD who have already received at least one line of therapy, addressing a population with an unmet treatment need. Under the proposed label, the treatment would be available to both adult and pediatric patients beginning at age two, if authorized by the FDA. Atara describes its broader platform as a way to develop investigational treatments for difficult-to-treat cancers and autoimmune conditions. The company states that its allogeneic T-cell platform does not require T-cell receptor or human leukocyte antigen (HLA) gene editing. While the BLA acceptance represents progress toward a possible U.S. authorization, the FDA’s review will determine whether the submitted evidence supports approval for the proposed patient population. Until a decision is made, Tab-cel remains investigational for this proposed U.S. indication.
Advertisement
Commercial Milestones and Partnership With Pierre Fabre
Atara and Pierre Fabre are continuing their commercialization partnership as the application moves through FDA review. If Tab-cel receives approval, Atara would be eligible for a $31 million milestone payment under its commercialization agreement with Pierre Fabre Laboratories. Atara could also receive significant double-digit tiered royalties on net sales and additional commercial sales milestone payments. These payments are contingent on the relevant contractual and commercial conditions being met and are not guaranteed by the application’s acceptance. Pierre Fabre Pharmaceuticals is responsible for the BLA submission and would support the potential U.S. commercialization effort, while Atara continues to provide support for the program. Atara is headquartered in Southern California and focuses on developing allogeneic T-cell therapies for cancer and autoimmune diseases. Its portfolio includes investigational programs built around its EBV-targeting platform. The company says its broader objective is to develop therapies that can be rapidly delivered to patients from available inventory. The upcoming FDA review will be a key next step for Tab-cel, with the March 31, 2027 PDUFA target date providing the current regulatory timeline. Any U.S. launch and associated commercial payments will depend on the outcome of that review and subsequent commercialization activities.
Source::Atara Biotherapeutics, press release
